Richard Casaburi.

Criner, M.D., Jeffrey L. Curtis, M.D., Tag T. Dransfield, M.D., MeiLan K. Han, M.D., Stephen C. Lazarus, M.D., Barry Make, M.D., Nathaniel Marchetti, M.D., Fernando J. Martinez, M.D., Nancy E. Madinger, M.D., Charlene McEvoy, M.D., M.P.H., Dennis E. Niewoehner, M.D., Janos Porsasz, M.D., Ph.D., Connie S. Price, M.D., John Reilly, M.D., Paul D. Scanlon, M.D., Frank C. Sciurba, M.D., Steven M. Scharf, M.D., Ph.D., George R. Washko, M.D., Prescott G. Woodruff, M.D., M.P.H., and Nicholas R.I only wish that my composing and other’s function will educate them to the emotional dynamic behind illness. For me it really is a mission, one that I am honored to be given.. Almirall submits linaclotide MAA to EMA for treatment of IBS-C Ironwood Pharmaceuticals, Inc. today announced that its European partner Almirall, S.A. Submitted a Advertising Authorization Program to the European Medicines Agency for linaclotide, a guanylate cyclase type-C agonist, for the treatment of irritable bowel syndrome with constipation . The submission includes efficacy and basic safety data from a Stage 3 program comprising two double-blind placebo-managed trials measured against the endpoints required by the EMA and two open-label long term safety studies.